DiaMedica Therapeutics (NASDAQ:DMAC) Now Covered by Analysts at Craig Hallum

Investment analysts at Craig Hallum assumed coverage on shares of DiaMedica Therapeutics (NASDAQ:DMAC) in a report released on Wednesday, StockNewsAPI reports. The brokerage set a “buy” rating and a $8.00 price target on the stock. Craig Hallum’s target price points to a potential upside of 226.53% from the company’s previous close.

Separately, Oppenheimer reissued an “outperform” rating and issued a $6.00 price target (down previously from $7.00) on shares of DiaMedica Therapeutics in a report on Thursday, March 21st.

DiaMedica Therapeutics Stock Up 1.2 %

Shares of NASDAQ:DMAC traded up $0.03 during trading on Wednesday, hitting $2.45. 1,972 shares of the stock traded hands, compared to its average volume of 41,261. The company has a market cap of $93.00 million, a price-to-earnings ratio of -3.90 and a beta of 1.69. The company has a fifty day moving average price of $2.81 and a two-hundred day moving average price of $2.70. DiaMedica Therapeutics has a 52-week low of $1.50 and a 52-week high of $4.75.

DiaMedica Therapeutics (NASDAQ:DMAC) last posted its earnings results on Wednesday, March 20th. The company reported ($0.14) earnings per share for the quarter, meeting the consensus estimate of ($0.14). On average, equities research analysts predict that DiaMedica Therapeutics will post -0.69 EPS for the current fiscal year.

Institutional Investors Weigh In On DiaMedica Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in DMAC. Avantax Advisory Services Inc. acquired a new stake in DiaMedica Therapeutics during the 4th quarter worth $36,000. Stonebridge Capital Advisors LLC acquired a new stake in DiaMedica Therapeutics during the 3rd quarter worth $52,000. Finally, Paragon Associates & Paragon Associates II Joint Venture boosted its stake in DiaMedica Therapeutics by 6.4% during the 4th quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 500,000 shares of the company’s stock worth $1,420,000 after purchasing an additional 30,000 shares during the last quarter. Hedge funds and other institutional investors own 10.12% of the company’s stock.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.